Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 pandemic has brought the world to a halt, and the race for a vaccine has been on since early 2020. Bolivia, like many other countries, has been eagerly awaiting the arrival of a vaccine to help curb the spread of the virus.
Customer preferences: The Bolivian population has shown a strong interest in getting vaccinated against COVID-19. However, there has also been a significant amount of misinformation and skepticism surrounding the vaccine. The government has been working to address these concerns through education campaigns and by prioritizing the vaccination of healthcare workers and other essential personnel.
Trends in the market: The COVID-19 vaccine market in Bolivia has been developing at a slower pace compared to other countries in the region. This can be attributed to a number of factors, including limited access to vaccines due to global supply chain issues and challenges in distributing the vaccine across the country's diverse geography. However, the government has been working to accelerate the pace of vaccination by securing additional doses from various sources.
Local special circumstances: Bolivia has a diverse population with many different ethnic groups and languages spoken throughout the country. This has presented unique challenges in terms of vaccine distribution and education campaigns. The government has been working to address these challenges by partnering with local organizations and community leaders to ensure that everyone has access to accurate information about the vaccine.
Underlying macroeconomic factors: Bolivia has been facing significant economic challenges in recent years, including high levels of poverty and inequality. The COVID-19 pandemic has only exacerbated these issues, with many people losing their jobs and struggling to make ends meet. The government has recognized the importance of vaccinating the population as a key step towards economic recovery, and has been working to secure funding to support the vaccination campaign.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
